Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 848

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 12
Chunk 848
---
izedLossesFairValueCurrent:Certificates of deposit$10,374 $11 $— $10,385 U.S. Treasuries173,465 153 (27)173,591 Government securities167,970 103 (75)167,998 Corporate debt securities465,427 321 (259)465,489 Total Current817,236 588 (361)817,463 Non-current:U.S. Treasuries107,725 106 (303)107,528 Government securities112,175 3 (469)111,709 Corporate debt securities420,166 181 (1,263)419,084 Total Non-current640,066 290 (2,035)638,321 Total marketable securities$1,457,302 $878 $(2,396)$1,455,784 

F-16

Marketable securities at December 31, 2023 consisted of the following:(In thousands)AmortizedCostUnrealizedGainsUnrealizedLossesFairValueCurrent:U.S. Treasuries$30,876 $— $(56)$30,820 Government securities247,460 194 (695)246,959 Corporate debt securities411,045 874 (975)410,944 Total Current689,381 1,068 (1,726)688,723 Non-current:U.S. Treasuries4,802 30 — 4,832 Government securities9,986 75 — 10,061 Corporate debt securities14,430 112 — 14,542 Total Non-current29,218 217 — 29,435 Total marketable securities$718,599 $1,285 $(1,726)$718,158 There were no material realized gains or losses on marketable securities for the years ended December 31, 2024 and 2023.At December 31, 2024 and 2023, we held 213 and 151 debt securities, respectively, that were in an unrealized loss position for less than one year. We did not record an allowance for credit losses as of December 31, 2024 and 2023 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2024 and 2023 was $